ADA 2024 DKA updates
Reading File
Checking Date & Time
Finding Sources
Searching PubMed
"diabetic ketoacidosis" AND "management" AND "guidelines"
Searching the Web
ADA 2024 Standards of Care diabetic ketoacidosis DKA updates changes
Finding Sources
Searching PubMed
"diabetic ketoacidosis" AND "ADA" AND "2024"
Reading Article
Reading Article
Reading File
Finding Sources
Searching PubMed
"diabetic ketoacidosis" AND "balanced crystalloid" AND "saline"
Reading File
Reading File
Reading File
I now have sufficient content from the textbooks and have the 2024 ADA/EASD/JBDS/AACE consensus report identified (PMID 39052901). Let me compile the comprehensive answer covering all the key 2024 updates.
ADA 2024 DKA: Key Updates from the Consensus Report
In August 2024, the ADA, EASD, JBDS, AACE, and Diabetes Technology Society (DTS) published a landmark joint consensus report updating DKA management for the first time since 2009:
Umpierrez GE et al. "Hyperglycemic Crises in Adults With Diabetes: A Consensus Report." Diabetes Care. 2024 Aug 1. PMID: 39052901
1. Revised Diagnostic Criteria
The 2024 consensus simplifies and broadens the DKA framework. The classic diagnostic triad remains:
- Hyperglycemia (glucose >250 mg/dL), though euglycemic DKA is now explicitly recognized (glucose <250 mg/dL, particularly with SGLT2 inhibitors)
- Ketonemia (β-hydroxybutyrate ≥3.0 mmol/L) or ketonuria (≥2+)
- Metabolic acidosis: venous pH <7.3 or bicarbonate <18 mmol/L
| Severity | pH | Bicarbonate | Mental Status |
|---|---|---|---|
| Mild | 7.25–7.30 | 15–18 | Alert |
| Moderate | 7.00–7.24 | 10–15 | Drowsy |
| Severe | <7.00 | <10 | Stupor/coma |
Key change: Direct measurement of β-hydroxybutyrate (rather than urine/serum nitroprusside-based tests) is now preferred for diagnosis and monitoring. The nitroprusside test does not detect β-hydroxybutyrate and can be falsely negative early or falsely positive during recovery.
2. Euglycemic DKA (eDKA) — Formal Recognition
The 2024 consensus explicitly addresses SGLT2 inhibitor–associated euglycemic DKA:
- Glucose is normal or only mildly elevated (<250 mg/dL), masking the diagnosis
- Mechanism: SGLT2 inhibitors promote glycosuria and glucagon secretion, driving ketogenesis despite near-normal glucose
- Precipitants: surgery, fasting, intercurrent illness, alcohol use, reduced insulin in T1D
- Management: Hold SGLT2 inhibitors, treat as standard DKA; glucose target during insulin infusion may need to be lower (e.g., start dextrose earlier)
3. Fluid Resuscitation — Shift Away from Normal Saline
This is one of the most significant clinical practice changes:
| Old Approach | 2024 Update |
|---|---|
| 0.9% NaCl (normal saline) as default | Balanced crystalloids preferred (lactated Ringer's or Plasmalyte) |
| Large NS volumes often cause hyperchloremic acidosis | Balanced solutions resolve DKA faster and reduce hyperchloremia |
A 2024 systematic review and meta-analysis confirmed faster DKA resolution with balanced electrolyte solutions vs. 0.9% saline (PMID: 38925619).
Practical points:
- Initial bolus: 1–1.5 L over 1 hour (isotonic fluid) for hemodynamic stabilization
- Subsequent fluids: 0.45% NaCl or balanced crystalloid at 250–500 mL/hr, guided by electrolytes and clinical status
- Add dextrose (5–10%) to IV fluid when glucose falls to 200–250 mg/dL (to allow continued insulin for ketosis clearance)
4. Insulin Therapy
| Aspect | 2024 Guidance |
|---|---|
| IV regular insulin | Still recommended for moderate–severe DKA |
| Subcutaneous rapid-acting insulin | Now explicitly endorsed as an alternative for mild–moderate DKA (if patient is alert and tolerating oral fluids) |
| Insulin bolus before infusion | An initial 0.1 units/kg IV bolus is optional, not mandatory |
| Rate | 0.1 units/kg/hr IV; reduce to 0.05 units/kg/hr once glucose <200–250 mg/dL |
| Transition to subcutaneous | Overlap subcut insulin with IV insulin by 1–2 hours before stopping infusion |
The use of subcutaneous insulin protocols (e.g., rapid-acting analogs every 1–2 hours) in mild DKA is a practical update that can enable treatment in lower-acuity settings.
5. Potassium Replacement
| Serum K+ | Action |
|---|---|
| <3.5 mEq/L | Hold insulin, replace K+ aggressively (20–40 mEq/hr IV) until ≥3.5 |
| 3.5–5.0 mEq/L | Start insulin + add K+ 20–30 mEq per liter IV fluid |
| >5.0 mEq/L | Start insulin, monitor closely, hold K+ supplementation |
This is unchanged in principle but the 2024 report reemphasizes that hypokalemia before insulin initiation is life-threatening and must be corrected first.
6. Bicarbonate — Not Recommended
The 2024 consensus discourages routine bicarbonate use, consistent with evidence showing no benefit and potential harm (paradoxical CNS acidosis, hypokalemia):
- Only consider if: pH <6.9, hemodynamic instability, or severe hyperkalemia
- Goldman-Cecil: "Bicarbonate administration should be considered only if ketoacidosis is accompanied by shock or if arterial pH is less than 7.0" — Goldman-Cecil Medicine, p. 2484
7. Resolution Criteria (Updated)
The 2024 consensus proposes clearer biochemical criteria for DKA resolution:
- Blood glucose <200–250 mg/dL
- β-hydroxybutyrate <0.6 mmol/L (preferred over bicarbonate normalization)
- Bicarbonate ≥15 mEq/L (or anion gap normalizing)
- Venous pH >7.3
- Patient able to tolerate oral intake
Using β-hydroxybutyrate for resolution (rather than waiting for urine ketones to clear) is a key practical update — urine ketones can remain positive for 24+ hours after true biochemical resolution.
8. Phosphate and Magnesium
- Phosphate: Routine replacement not recommended. Consider if <1.0 mg/dL, respiratory failure, or cardiac dysfunction. — Goldman-Cecil Medicine
- Magnesium: Replace if hypomagnesemia is present; supports potassium correction
9. Cerebral Edema
- More common in children; rare in adults
- Risk factors: rapid fluid administration, younger age, lower initial CO₂
- 2024 guidance: no evidence to withhold appropriate fluid resuscitation in adults based on cerebral edema risk
- Treatment: hypertonic saline or mannitol if suspected
10. Precipitant Identification and Prevention
Common precipitants per the 2024 report:
- Infection (most common)
- Insulin omission / nonadherence
- New-onset T1D
- SGLT2 inhibitors (euglycemic DKA)
- Acute coronary syndrome, pancreatitis, drugs (corticosteroids, atypical antipsychotics)
Sick-day management rules and structured diabetes education during admission are emphasized for prevention of recurrence.
Summary of Key Changes vs. Prior Guidelines
| Domain | Pre-2024 | 2024 Update |
|---|---|---|
| Fluids | Normal saline default | Balanced crystalloids preferred |
| Insulin route (mild) | IV standard | SubQ acceptable |
| Ketone monitoring | Urine/serum nitroprusside | β-hydroxybutyrate (point-of-care) preferred |
| Resolution endpoint | Bicarbonate/AG normalization | β-hydroxybutyrate <0.6 mmol/L preferred |
| Euglycemic DKA | Underemphasized | Formally defined, SGLT2i context |
| Bicarbonate use | Controversial | Not recommended (except pH <6.9 / shock) |
Sources:
- Umpierrez GE et al. Diabetes Care 2024; ADA/EASD/JBDS/AACE/DTS Consensus [PMID: 39052901]
- Szabó GV et al. Diabetes Metab Res Rev 2024 — Balanced solutions meta-analysis [PMID: 38925619]
- Goldman-Cecil Medicine, 26th ed., Chapter 210
- Rosen's Emergency Medicine, 9th ed.
- Ciafardini A et al. Endocr Metab Immune Disord Drug Targets 2025 — Residual controversies post-consensus [PMID: 40257014]
This is a shared conversation. Sign in to Orris to start your own chat.